Endo Pharmaceuticals and Bioniche Life Sciences announced enrollment of the first patient into their Phase 3 study of Urocidin in the intravesical treatment of patients with BCG (Bacillus Calmette-Guérin) recurrent or refractory non-muscle-invasive bladder cancer. The trial is a randomized, active-controlled, open-label, multicenter study with a blinded endpoint assessment designed to compare Urocidin with mitomycin C.  This trial is expected to enroll 450 patients at approximately 120 clinical sites worldwide. 

Urocidin is a formulation of MCC, a sterile mycobacterial cell wall-DNA complex composition that has a dual mode of action: immune stimulation and direct anticancer activity. 

For more information call (800) 462-ENDO or visit www.endo.com.